Open Access Open Access  Restricted Access Subscription or Fee Access

Recent studies of drugs in type II Diabetes

A Saranya, Dr.S. Kameshwaran, S. Shameem, K. Shanmugapriya, K.P. Sathish, S.M. Shabariraj


Diabetes is a chronic disease that has an impact on how your body uses food as fuel. A chronic metabolic disease called diabetes mellitus (DM) is characterised by persistent hyperglycemia.Your body converts the bulk of the food you eat into sugar (glucose), which is subsequently released into your circulation. When your blood sugar levels increase, your pancreas releases insulin. Type 2 diabetes symptoms may take years to manifest. Some individuals seldom ever show any symptoms. Despite the fact that type 2 diabetes affects children and teenagers more frequently, it typically strikes adults first. Because the symptoms of type 2 diabetes are subtle, understanding the risk factors is essential. A visit to the doctor is necessary for any of them. Taking insulin or other diabetes drugs is commonly part of diabetes treatment.


Diabetes, Pancreas, Chronic Metabolic Illness, Bloodstream, Type 2 diabetes

Full Text:



Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018 Feb;14(2):88-98.

Maitra A, Abbas AK. Endocrine system. In: Kumar V, Fausto N, Abbas AK (eds). Robbins and Cotran Pathologic basis of disease (7th ed) 2005. Philadelphia, Saunders; 1156-1226

Reaven GM. 1998 The role of insulin resistance in human disease. Diabetes. 37:1595–1607.

Olefsky JM. 1989 Pathogenesis of non-insulin dependent diabetes (type 2). In: DeGroot LJ, Besser GM, Cahill JC, eds. Endocrinology, 2nd ed. Philadelphia: Saunders; 1369–1388.

Gardner DG, Shoback D, eds. (2011). “Chapter 17: Pancreatic hormones & diabetes mellitus”. Greenspan’s basic & clinical endocrinology (9th ed.). New York: McGraw-Hill Medical. ISBN 978-0-07-162243-1. OCLC 613429053. 6. on Jul 1. 7.Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–820. Doi:10.1038/414813a.

K. D Thirapathi. Essential of medical pharmacology. Eighth edition. 9.Singh G, Krauthamer M, Bjalme-Evans M (January 2022).”Wegovy (semaglutide): a new weight loss drug for chronic weight management”Journal of Investigative Medicine. 70 (1): 5–13. Doi:10.1136/jim-2021-001952.

Phillips A, Clements JN (February 2022). “Clinical review of subcutaneous semaglutide for obesity”. Journal of Clinical Pharmacy and Therapeutics. 47 (2): 184–193. Doi:10.1111/jcpt.13574 11.Amaro A, Sugimoto D, Wharton S (January 2022). “Efficacy and safety of semaglutide for weight management: evidence from the STEP program”. Postgraduate Medicine. 134 (sup1): 5–17. Doi:10.1080/00325481.2022.2147326.

”Ozempic- semaglutide injection, solution”DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021.

Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. (September 2015). “Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide”. Journal of Medicinal Chemistry. 58 (18): 7370–80. Doi:10.1021/acs.jmedchem.5b00726. 14.”Wegovy- semaglutide injection, solution”DailyMed. 4 June 2021. Archived from the original on 14 December 2021. Retrieved 11 March 2022.

”WegovyEPAR”European Medicines Agency. 11 November 2021. Archived from the original on 2 July 2022. Retrieved 11 March 2022. 16.”FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014”. U.S. Food and Drug Administration (FDA) (Press release). 4 June 2021. Archived from the original on 4 June 2021. Retrieved 5 June 2021.

Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. (SURPASS-2 Investigators) (August 2021). “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes”. The New England Journal of Medicine. 385 (6): 503–515. Doi:10.1056/NEJMoa2107519.

Lee YS, Jun HS: Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism. 2014 Jan;63(1):9-19. Doi: 10.1016/j.metabol.2013.09.010. Epub 2013 Oct 17.

FDA Press Announcements: FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 .

Jensen L, Helleberg H, Roffel A, van Lier JJ, Bjornsdottir I, Pedersen PJ, Rowe E, DervingKarsbol J, Pedersen ML: Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017 Jun 15;104:31-41. Doi: 10.1016/j.ejps.2017.03.020. Epub 2017 Mar 16. 21. on Jul 3. 22. on Jul 5. 23.”Mounjarotirzepatideinjection,solution”DailyMed. 13 May 2022. Archived from the original on 3 July 2022. Retrieved 27 May 2022. 24.”FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes”Food and Drug Administration(FDA) (Press release). 13 May 2022. Archived from the original on 13 May 2022. Retrieved 13 May 2022.

Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. (January 2021). “Dual GIP and GLP-1 Receptor Agonist TirzepatideImproves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes”. The Journal of Clinical Endocrinology and Metabolism. 106 (2): 388–396. Doi:10.1210/clinem/dgaa863.

Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. (December 2018). “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept”. Molecular Metabolism. 18: 3–14. Doi:10.1016/j.molmet.2018.09.009.

”Drug Trials Snapshots: Mounjaro”U.S. Food and Drug Administration (FDA). 13 June 2023. Retrieved 14 June 2023.

Sun B, Willard FS, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, Ho JD, Showalter AD, Stutsman C, Ding L, Suter TM, Dunbar JD, Carpenter JW, Mohammed FA, Aihara E, Brown RA, Bueno AB, Emmerson PJ, Moyers JS, Kobilka TS, Coghlan MP, Kobilka BK, Sloop KW. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022 Mar 29;119(13):e2116506119. 29.Bucheit J, Ayers J, Pamulapati L, Browning A, Sisson E. A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. J Cardiovasc Pharmacol. 2022 Aug 01;80(2):171-179.

.,your%20doctor%20or%20pharmacist%20promptly.Retrieved on Jul 6. 31. Retrieved on Jul 7.

Vuylsteke V, Chastain LM, Maggu GA, Brown C (September 2015). “Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes”. Drugs in R&D. 15 (3): 227–32.Doi:10.1007/s40268-015-0099-3.

Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K (April 2021). “Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial”. Diabetes Care. 44 (4): 952–959. Doi:10.2337/dc20-0763. 34.Poxel SA (June 23, 2021). “Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan” (Press release).

V. Pirags, H. Lebovitz, and P. Fouqueray, “Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients,” Diabetes, Obesity and Metabolism, vol. 14, no. 9, pp. 852–858, 2012.

P. Fouqueray, V. Pirags, S. E. Inzucchi et al., “The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy,” Diabetes Care, vol. 36, no. 3, pp. 565–568, 2013.

P. Fouqueray, V. Pirags, M. Diamant et al., “The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy,” Diabetes Care, vol. 37, no. 7, pp. 1924–1930, 2014.

V. Vuylsteke, L. M. Chastain, G. A. Maggu, and C. Brown, “Imeglimin: a potential new multi-target drug for type 2 diabetes,” Drugs in R&D, vol. 15, no. 3, pp. 227–232, 2015.

Hallakou‐Bozec S, Vial G, Kergoat M, et al. Mechanism of action of imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes ObesMetab. 2021;23:664‐673.

Vial G, Chauvin M‐A, Bendridi N, et al. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high‐fat, high‐sucrose diet mice model. Diabetes. 2015;64:2254‐2264.

Hallakou‐Bozec S, Kergoat M, Moller DE, Bolze S. Imeglimin preserves islet β‐cell mass in type 2 diabetic ZDF rats. Endocrinol Diabetes Metab. 2020;4:e00193.

Fouqueray P, Leverve X, Fontaine E, et al. Imeglimin ‐ a new oral anti‐diabetic that targets the three key defects of type 2 diabetes. J Diabetes Metab. 2011;2:126.

Fouqueray P, Perrimond-Dauchy S, Bolze S. Imeglimin does not induce clinically relevant pharmacokinetic interactions when combined with either metformin or sitagliptin in healthy subjects. Clin Pharmacokinet. 2020;59(10):1261–71.

Clemence C, Fouqueray P, Sebastien B. In vitro investigation, pharmacokinetics, and disposition of imeglimin, a novel oral antidiabetic drug, in preclinical species and humans. Drug MetabDispos. 2020;48(12):1330–46.

Chevalier C, Perrimond-Dauchy S, Dubourg J, Fouqueray P, Bolze S. Lack of drug–drug interaction between cimetidine, a renal transporter inhibitor, and imeglimin, a novel oral antidiabetic drug, in healthy volunteers. Eur J Drug MetabPharmacokinet. 2020;45(6):725–33.

Dubourg J, Ueki K, Grouin JM, Fouqueray P. Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial. Diabetes ObesMetab 2021;23:800–810. 47. on Jul 8. Retrieved on: Jul 92023. on : Jul 10 2023.

Zhang W, Li X, Ding H, Lu Y, Stilwell GE, Halvorsen YD, Welihinda A: Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans. Xenobiotica. 2020 May;50(5):559-569. doi: 10.1080/00498254.2019.1654634.

FDA Approved Drug Products: BRENZAVVY (bexagliflozin) tablets for oral. on : Jul 11 2023.

. on :Jul 12 2023. 53.”Novel Drug Approvals for 2023” US Food and Drug Administration(FDA). 20 January 2023. Retrieved 21 January 2023.


  • There are currently no refbacks.

Copyright (c) 2023 Research & Reviews: A Journal of Pharmacology